Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study

Autor: M. Laguno, M.A. Von Wichmann, E. Van den Eynde, J. Navarro, C. Cifuentes, J. Murillas, S. Veloso, M. Martínez-Rebollar, J.M. Guardiola, A. Jou, J.L. Gómez-Sirvent, M. Cervantes, J.A. Pineda, S. López-Calvo, A. Carrero, M.L. Montes, E. Deig, A. Tapiz, J.D. Ruiz-Mesa, A. Cruceta, E. de Lazzari, J. Mallolas

Publikováno v: International Journal of Infectious Diseases, Vol 53, Iss C, Pp 46-51 (2016)

Introduction: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-α2a/ribavirin (PEG-IFN/RBV) in the retreatment of

Externí odkaz: https://doaj.org/article/05b17d5d28db44e8ba709ee912443059

Psychological distress in women and men living with HIV in Spain: a cross-sectional telephone survey [Postprint]

Autor: Dante Culqui Lévano, María J Pérez-Elías, J.L. Gómez-Sirvent, Marta Montero, Alejandro Peña-Monje, Maria Ángeles Rodríguez-Arenas, Jorge del Romero, Cesar Garriga, Lourdes Gutiérrez Trujillo, José Ramón Blanco, Félix Gutiérrez

Publikováno v: Repisalud
Instituto de Salud Carlos III (ISCIII)
Evidence-Based Mental Health
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Psychological distress includes a broader range of experiences, varying from less severe symptoms of depression and anxiety to severe psychiatric disease. Global estimates for depression and anxiety in 2017 were 3.4% and 3.8%, respectively. While for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0a01d95d3c0213e26604a9e3424a127
http://hdl.handle.net/20.500.12105/11579

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice

Autor: CoRIS, Melchor Riera, J.L. Gómez-Sirvent, Nuria Espinosa, Joaquim Peraire, Julián Olalla, Natalia Chueca, Carlos Guerrero-Beltran, Silvia García-Bujalance, Mónica García-Álvarez, David Dalmau, Adrian Curran, David Vinuesa, Arkaitz Imaz, María J Pérez-Elías, Eva Poveda, Antonio Aguilera, José Ramón Blanco, Adolfo de Salazar, Paz Casas, Gemma Navarro, Irene Portilla, Félix Gutiérrez, Jesús Santos, Carlos Galera, Marta Álvarez, Carmen Rodríguez, José Miguel Molina, Federico García, Lucio García-Fraile, José Antonio Iribarren, Beatriz Pierola

Publikováno v: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante

Background: Integrase strand-transfer inhibitors (INSTIs) constitute at present one of the pillars of first-line ART. Objectives: To study the prevalence of and the trend in transmitted drug resistance (TDR) to INSTIs in ART-naive patients in Spain.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1a7b58903f264969e7aaebeaf50b0a6
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=4611